RR-June-2023-Cover

Regulatory Rapporteur

 

Write to the Editor at publications@topra.org

June 2023   |   Volume 20   |   No.6

 
 

MEM18-Red-Linkedin-Cover-1128x191px

 
 

RR-JUNE-2023-COVER

EDITORIAL

Clinical trials:
Ethical, ecological and economic change

In the pursuit of global – or even regional – standards in requirements to support medical product development; is industry keeping up? Can regulations and guidelines keep up with the pace of change?

READ HERE
By Sarah Roberts

 

AdobeStock_378723672 (1)

FOCUS

Decentralised clinical trials –
an EU recommendation paper

Decentralised clinical trials (DCTs) have undergone rapid development over the last three years, bringing benefits to patients, sites, and sponsors. This article provides EU guidance for conducting DCTs and recommendations for protocol and informed consent.

READ HERE
By Pedro Barroso Inacio and Stefani Dilova 

 

RegRap-Call-for-Papers-November-v3

 

 

AdobeStock_349033382 (1)

FOCUS

First experiences with the Clinical Trial
Regulation – a company perspective

The Clinical Trials Regulation (CTR) replaced the Clinical Trials Directive (CTD) in January 2022. This article reports on Merck KGaA’s early experience with clinical trial applications (CTA) under the CTR, compared to its previous experience with CTAs under the CTD.

READ HERE

By Christopher Price, Elmar Schmitt, Martina Hoeth,
Georgios Amexis, Alexa Hunter
and Lisette Vromans

 

AdobeStock_508276010 (1)

FOCUS

Regulation (EU) No 536/2014 –
first experience from a CRO perspective

The EU Clinical Trials Regulation (CTR), effective from 31 January 2022, has introduced significant changes to the clinical trials application process. This article summarises the experience gathered under the CTR from the perspective of a contract research organisation.

READ HERE
By Ana Velimirovic, Britta Dieckhoff, Elisaveta Parapiteva,
Iris Romero Matuschek, Polly Halliday
and Vicki Iassonidou

 

AdobeStock_367097266

FOCUS

Processes when seeking scientific
advice in the EU and USA –
is there a difference and does it matter?

All major regulatory agencies provide scientific advice to pharmaceutical companies developing new medicines. The EMA and FDA have different procedural approaches to scientific advice, meaning that companies seeking advice must tailor their plans. This research paper compares the two agencies’ procedural appraoches. This is the first article in a two-part series.

READ HERE
By Hilary Gray

 

Med-Devices

FEATURE

Medical device standards update

This edition of our regular feature updates on the progress of applicable standards for medical devices and in vitro diagnostic devices to March 2023.

READ HERE
By Mehyrar Behizad

 

AdobeStock_86056969

FEATURE

Reappraisal of regulation of agricultural
and veterinary chemicals in Australia

The Agricultural and Veterinary (Agvet) Chemicals Legislation Amendment (2014) means that Agvet products receive reapproval unless new evidence demonstrates harm to Australia’s environment. This article summarises this legislation and its impact on Australia’s Agvet market.

READ HERE
By Syed Ziauddin Hashmi

 
 

Informz-1130x220px